Amanote Research
Register
Sign In
P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations With Non-Adenocartinoma Histology
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.10.096
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
December 1, 2018
Authors
T. Yamaguchi
S. Morikawa
O. Yuko
K. Asada
T. Oguri
N. Inui
K. Ito
T. Kimura
E. Kunii
T. Matsui
A. Kubo
T. Kato
J. Shindo
T. Tsuda
M. Okuno
T. Hida
K. Imaizumi
Publisher
Elsevier BV
Related search
OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
Oncologist
Cancer Research
Medicine
Oncology
P3.13-23 EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.13-21 Clinical Efficacy and Safety of Apatinib Combined With EGFR - TKIs in Advanced Non-Small Cell Lung Cancer With EGFR - TKIs Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA07.06 Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Activation of the BMP-BMPR Pathway Conferred Resistance to EGFR-TKIs in Lung Squamous Cell Carcinoma Patients With EGFR Mutations
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary